Search Results
Your search for The ASCO ,The ASCO matches 20586 pages
Showing 6551 - 6600Responding to Racism and Health Inequality as a Cancer Care Community
On June 3, 2020, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, issued a statement on racism and health inequality. An excerpt from the statement follows: Months ago, when I defined a theme for my year as ASCO President, “Equity:Every Patient. Every Day. Everywhere,” I never imagined we would...
Palliative Care Resource for Your Patients From ASCO
Do your patients know that supportive care can help them manage the symptoms and side effects of cancer and treatment, regardless of their age, cancer type, or disease stage? Help your patients understand the benefits of palliative care and where to access these services with the ASCO Answers...
Mark Lewis, MD, and Jonathan Bleeker, MD, Reflect in ‘From Every Angle’
Mark Lewis, MD, was 8 years old when his father was diagnosed with cancer. Decades later, he was 1 week into an oncology fellowship when he self-diagnosed his own rare cancer, multiple endocrine neoplasia type 1 (MEN1). In the latest Your Stories podcast from Conquer Cancer, the ASCO Foundation,...
Small Goals, Big Victories
While working toward the goal of conquering cancer, patients often celebrate smaller victories. These wins can range from spending a holiday weekend with family to taking a vacation without restrictions. Jyoti Malhotra, MD, MPH, is a 2015 Young Investigator Award (YIA) recipient helping patients...
Leading Organizations Release New Clinical Guideline on Advanced Prostate Cancer
The American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) recently announced a new clinical practice guideline for the diagnosis and treatment of advanced prostate cancer. Prostate cancer is one of the most commonly diagnosed...
Role of Rituximab in the Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
Minard-Colin et al recently reported for the European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma...
If You Have Self-Doubt When Caring for a Loved One With Cancer
When taking care of a loved one with cancer, it’s natural to feel flooded with emotions—grief, guilt, and just plain old exhaustion. Feelings of inadequacy, doubt, or fear can sometimes pop up, too. Maybe you feel like you do not have the necessary skills to be a caregiver; maybe you feel like you...
New Guideline for Locally Advanced Esophageal Cancer Supports Multimodality Therapy and Multidisciplinary Treatment
ASCO has released a new guideline for the treatment of locally advanced esophageal cancer that will provide a context for the current standards of care, fill gaps in clinicians’ knowledge of therapy options, and help define future treatment.1 An expert panel developed the guideline based on 17...
USC Norris Comprehensive Cancer Center Receives $5 Million for Cancer Drug Discoveries
The University of Southern California (USC) Norris Comprehensive Cancer Center, Keck Medicine of USC, and the Keck School of Medicine of USC announced a $5 million gift from the Rosalie and Harold Rae Brown Charitable Foundation. The gift was received from Harold R. Brown, trustee of the...
Fox Chase Cancer Center Welcomes Two New Staff Members
Fox Chase Cancer Center, part of the Philadelphia-based Temple University Health System, recently announced two new additions to its staff. Shazia K. Nakhoda, MD, a graduate of the Fox Chase–Temple Hematology/Oncology Fellowship Program, joins the center’s Department of Hematology/Oncology in the...
Joann Sweasy, PhD, Named Director of University of Arizona Cancer Center
Joann Sweasy, PhD, who has served as Interim Director for the past 9 months, has been named Director of the University of Arizona Cancer Center and the inaugural holder of the Nancy C. and Craig M. Berge Endowed Chair for the Director of the Cancer Center. As Director, Dr. Sweasy will establish the ...
Marilyn J. Heine, MD, FACEP, FACP, FCPP, Elected AMA Council on Legislation Chair
During its June meeting, the American Medical Association (AMA) Council on Legislation chose Marilyn J. Heine, MD, FACEP, FACP, FCPP, as its new Chair. The Council reviews proposed federal legislation and recommends appropriate action in accordance with AMA policy. It also develops model state...
Yale Cancer Center Awarded NIH SPORE Renewal for Lung Cancer Research
Yale Cancer Center researchers were awarded an $11 million grant renewal from the National Institutes of Health to fund the Yale Specialized Program of Research Excellence (SPORE) in Lung Cancer. SPORE harnesses the strengths of academic cancer centers by bringing together experts in oncology,...
Expert Point of View: Marcus Noel, MD, and Susan Tsai, MD, MHS
Marcus Noel, MD, Associate Professor of Medicine at Lombardi Comprehensive Cancer Center and MedStar Georgetown University Hospital, Washington, DC, included SWOG S1505 in the presentation of the Gastrointestinal Cancer Highlights during the ASCO20 Virtual Scientific Program. Susan Tsai, MD, MHS, ...
Blood Cancer Discoveries Program Names Grant Recipients
The Leukemia & Lymphoma Society, the Mark Foundation for Cancer Research, and the Paul G. Allen Frontiers Group recently announced the awarding of more than $6.75 million to nine scientists. Each project will be supported by an award of $750,000 over a 3-year period. Grant Recipients The Blood ...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros highlight the rare primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS). For each ...
Epigenetics Researcher Yang Shi, PhD, Appointed Member of Ludwig Institute for Cancer Research
Yang Shi, PhD, recently joined the Oxford Branch of the United Kingdom’s Ludwig Institute for Cancer Research. Dr. Shi, who comes to Ludwig from Harvard University, is a leader in the field of epigenetics, which explores how chemical modifications made to chromatin control the organization and...
NYU Langone Health’s Perlmutter Cancer Center Welcomes Janice M. Mehnert, MD, as Associate Director for Clinical Research
Janice M. Mehnert, MD, a researcher in early-phase therapeutics and the treatment of skin malignancies, has been appointed Associate Director for Clinical Research at New York University Langone Health’s Perlmutter Cancer Center. Dr. Mehnert was Associate Professor of Medicine at Robert Wood...
ESMO Names George Pentheroudakis, MD, PhD, New Chief Medical Officer
The European Society for Medical Oncology (ESMO) has announced the appointment of George Pentheroudakis, MD, PhD, as its new Chief Medical Officer. Dr. Pentheroudakis is Head of the Department of Medical Oncology at the Ioannina University Hospital in Greece and serves as Professor of Oncology at...
Bishal Gyawali, MD, PhD, Receives Young Health Researcher Award From Nepali Government
At the Sixth National Summit of Health and Population Scientists, held in Kathmandu, Nepal, Bishal Gyawali, MD, PhD, was awarded the Mrgendra Samjhana Medical Trust Young Researcher Award. The annual conference is organized by the Nepal Health Research Council, an autonomous body of the Government...
Expanded Access to Cancer Drugs in Africa and Asia
The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) announced agreements with the pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 cancer drugs in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59%...
Robert Winn, MD, Joins LUNGevity Foundation’s Board of Directors
The LUNGevity Foundation recently announced that Robert Winn, MD, Director of the Virginia Commonwealth University (VCU) Massey Cancer Center, has joined the foundation’s Board of Directors. The nation’s leading lung cancer–focused nonprofit organization, LUNGevity Foundation is dedicated to...
Expert Point of View: Komal Jhaveri, MD
“Surprisingly, the phase II PARSIFAL trial did not show a statistical superiority in progression-free survival for fulvestrant plus palbociclib over letrozole plus palbociclib in the first-line treatment of patients with endocrine-sensitive, metastatic breast cancer. The noninferiority hypothesis...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
AACR Holds COVID-19 and Cancer Virtual Meeting
The American Association for Cancer Research (AACR) hosted a virtual meeting on COVID-19 and cancer earlier this month (July 20–22, 2020). The virtual event, “COVID-19 and Cancer,” featured presentations from leaders in the fight against the pandemic, including three keynote lectures. In an opening ...
ASTRO to Host Virtual Annual Meeting, October 25–28, 2020
The American Society for Radiation Oncology (ASTRO) has announced it will hold its 62nd Annual Meeting October 25–28, 2020, via an interactive virtual platform. The meeting, “Global Oncology: Radiation Therapy in a Changing World,” will feature reports from the latest clinical trials; panels on...
Monumental Progress in the Treatment of Diffuse Large B-Cell Lymphoma
Some monuments are difficult to topple. At least that was the case dating back to 1976, when investigators from the Southwest Oncology Group demonstrated the importance of doxorubicin in the treatment of patients with a group of lymphoid malignancies then referred to as diffuse aggressive...
The Need for Solid Data During a Global Pandemic
The rapid outbreak of COVID-19 disease on a global scale found the community of clinicians and scientists largely unprepared to face the devastating effects of the pandemic. The stress on health-care systems revealed their weaknesses and brought about associated financial crises. Defining the...
Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know
Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.
T-DM1 in Patients With HER2-Positive Breast Cancer and Brain Metastases: KAMILLA Trial
An exploratory subgroup analysis of the KAMILLA trial represents the largest reported cohort of patients with HER2-positive breast cancer and brain metastases treated with the anti-HER2 antibody-drug conjugate ado-trastuzumab emtansine, or T-DM1, in a prospective setting. Researchers observed...
Updated CCC19 Data Offer Insights on Treatment for Patients With Cancer and COVID-19 Infection
Newly released data on treatment outcomes of patients with cancer infected with COVID-19 revealed a racial disparity in access to remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite...
Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?
Adam C. Palmer, PhD, of the University of North Carolina at Chapel Hill, discusses combining immune checkpoint inhibitors with other cancer therapies to provide patients with more chances of a response. In principle, similar benefits may result from sequential or biomarker-stratified treatments,...
Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting
Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are...
EAU Virtual: EUPROMS Study Investigates Effect of Prostate Cancer Treatment on Quality of Life
Findings from the first international prostate cancer quality-of-life study showed that significant numbers of men treated for the disease are struggling with continence and sexual problems after treatment. Results suggest that any treatment apart from active surveillance may negatively affect...
Miguel-Angel Perales, MD, and Syed A. Abutalib, MD, on Bone Marrow Transplants During the COVID-19 Pandemic
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, talks with Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, about the challenges and concerns related to transplants for patients with hematologic malignancies who are particularly vulnerable to infection with the...
ASCO and ACCC Join Forces to Increase Participation of Racial and Ethnic Minority Populations in Cancer Treatment Trials
The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) have announced a new collaboration to foster participation in oncology clinical trials to more fully reflect the diversity of people at risk for or living with cancer. The joint ASCO-ACCC initiative...
Andrew H. Wei, MBBS, PhD, on AML: Venetoclax Plus Cytarabine in Older Patients
Andrew H. Wei, MBBS, PhD, of The Alfred Hospital, Monash University, discusses phase III data from the VIALE-C trial, which appear to support the use of venetoclax plus low-dose cytarabine as a front-line treatment for older patients with acute myeloid leukemia, as well as for those who cannot...
FDA Pipeline: Novel Treatments for Hematologic Malignancies
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to pembrolizumab for the second-line treatment of patients with relapsed or refractory Hodgkin lymphoma, and also accepted a supplemental new drug application for selinexor for pretreated patients with multiple myeloma....
Eric Zhou, PhD, on Insomnia in Young Cancer Survivors: Online Program May Improve Quality of Life
Eric Zhou, PhD, of Dana-Farber Cancer Institute, discusses an existing online program called SHUTi (Sleep Healthy Using the Internet), that he and his team adapted to the needs of adolescent and young adult cancer survivors. After six online cognitive behavior therapy sessions delivered over 8...
SNMMI 2020: First Results of Total-Body Dynamic PET Scan in Patients With Cancer
Results from the first study using uEXPLORER to conduct total-body dynamic positron-emission tomography (PET) scans in patients with cancer suggested that it can be used to generate high-quality images of metastatic cancer. The research was presented at the Society of Nuclear Medicine and Molecular ...
SNMMI 2020: Role of PSMA PET/CT in the Management of Recurrent Prostate Cancer
New research outlines the role of prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) in the detection and management of recurrent disease in prostate cancer patients. In initial results from a multicenter trial assessing the impact of F-18 DCFPyL...
SNMMI 2020: Novel PET Radiotracer for Glioblastoma
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting and published by Zhang et al in the Journal of Nuclear Medicine has demonstrated the safety and favorable pharmacokinetic and dosimetry profile of Cu-64 EBRGD, a new, relatively...
Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting
Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on...
Study Links Mental Health Treatment to Possible Improved Cancer Survival
For people with cancer who have a mental health disorder, getting mental health treatment may help them live longer, a new study published by Berchuck et al in JAMA Oncology suggests. In the retrospective study, of more than 50,000 veterans treated for lung cancer within the Veterans Affairs (VA)...
Study Identifies Factors That May Predict Toxicities in Patients Treated With CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has proved to be a valuable treatment option for patients with lymphoma in whom other therapies have failed. In clinical trials, the cellular immunotherapy was shown to provide durable remissions for nearly 40% of patients with large B-cell lymphoma....
Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges
Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.
Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges
Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.
Two Studies Focus on Emerging Treatment Options for Patients With Neuroendocrine Tumors
Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, and published in Oncotarget and Cancer, respectively, highlight possible new treatment options for patients with neuroendocrine tumors. SurVaxM The first report,...
Lung Cancer in Nonsmoking Individuals: Differences in Genetics and Response to Treatment
Lung cancer in nonsmokers is a diverse and distinct disease from lung cancer in smokers and is likely to respond differently to targeted treatments, according to results from a new study published by Chen et al in the journal Cell. Scientists studied a patient population in Taiwan with high rates...
Experimental COVID-19 Vaccine Generates Immune Response, Deemed Safe in Phase I Trial
According to a press release from the National Institutes of Health, an investigational vaccine designed to protect against SARS-CoV-2, the virus that causes COVID-19—mRNA-1273—was generally well tolerated and prompted neutralizing antibody activity in healthy adults. These interim results were...
